Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin Lymphoma

• Type of Material: Article
• Authors: Reid W. Merryman, Dana Farber Cancer Institute; Nicole A. Carreau, NY Cancer & Blood Specialists; Ranjana H. Advani, Stanford University; Michael A. Spinner, Stanford University; Alex F. Herrera, City of Hope National Medical Center; Robert Chen, City of Hope National Medical Center; Sarah Tomassetti, City of Hope National Medical Center; Radhakrishnan Ramchandren, Karmanos Cancer Institute; Muhammad Hamid, Karmanos Cancer Institute; Sarit Assouline, McGill University; Raoul Santiago, McGill University; Nina Wagner-Johnston, Johns Hopkins University; Suman Paul, Johns Hopkins University; Jakub Svoboda, Hospital of the University of Pennsylvania; Steven M. Bair, Hospital of the University of Pennsylvania; Stefan K. Barta, Fox Chase Cancer Center; Yang Liu, Emory University; Sunita Nathan, Rush University; Reem Karmali, Northwestern University; Madelyn Burkart, Northwestern Memorial Hospital; Pallawi Torka, Roswell Park Comprehensive Cancer Center; Kevin A. David, Rutgers Cancer Institute of New Jersey; Catherine Wei, Rutgers Cancer Institute of New Jersey; Frederick Lansigan, Dartmouth Hitchcock Medical Center; Lukas Emery, Dartmouth Hitchcock Medical Center; Daniel Persky, University of Arizona; Sonali M. Smith, University of Chicago; James Godfrey, University of Chicago; Julio Chavez, H. Lee Moffitt Cancer Center and Research Institute; Jonathon Cohen, Emory University; Andrea B. Troxel, New York University; Catherine Diefenbach, New York University; Philippe Armand, Dana Farber Cancer Institute
• Language: English
• Date: 2020-04-28
• Publisher: Wiley
• Publication Version: Final Published Version
• Copyright Statement: © AlphaMed Press 2020.
• Final Published Version (URL): http://dx.doi.org/10.1634/theoncologist.2020-0040
• Title of Journal or Parent Work: The Oncologist
• Volume: 25
• Issue: 6
• Start Page: E993
• End Page: E997
• Grant/Funding Information: P.A. gratefully acknowledges the support of the Harold and Virginia Lash Foundation, as well as the Leukemia and Lymphoma Society.; R.W.M. gratefully acknowledges support from an ASH Research Training Award for Fellows, the ASH Clinical Research Training Institute, an ASBMT New Investigator Award, and the LRF Lymphoma Clinical Research Mentoring Program.
• Keywords: Life Sciences & Biomedicine; Oncology; Transplantation; Science & Technology; PHASE-II; Efficacy; Nivolumab
• Research Categories: Health Sciences, Immunology; Health Sciences, Oncology; Health Sciences, Medicine and Surgery

Abstract

Atypical response patterns following immune checkpoint blockade (ICB) in Hodgkin lymphoma (HL) led to the concept of continuation of treatment beyond progression (TBP); however, the longitudinal benefit of this approach is unclear. We therefore performed a retrospective analysis of 64 patients treated with ICB; 20 who received TBP (TBP cohort) and 44 who stopped ICB at initial progression (non-TBP cohort). The TBP cohort received ICB for a median of 4.7 months after initial progression and delayed subsequent treatment by a median of 6.6 months. Despite receiving more prior lines of therapy, the TBP cohort achieved longer progression-free survival with post-ICB treatment (median, 17.5 months vs. 6.1 months, p =.035) and longer time-to-subsequent treatment failure, defined as time from initial ICB progression to failure of subsequent treatment (median, 34.6 months vs. 9.9 months, p =.003). With the limitations of a retrospective study, these results support the clinical benefit of TBP with ICB for selected patients.